TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02634190

Intervention type: OTHER
Intervention: Thinprep® LBC
Description: liquid based cytology

Intervention type: OTHER
Intervention: Thinprep® LBC
Description: liquid based cytology

Intervention type: OTHER
Intervention: APTIMA® HPV Assay
Description: in vitro diagnostic test

Intervention type: OTHER
Intervention: APTIMA® HPV Assay
Description: in vitro diagnostic test

Intervention type: OTHER
Intervention: HR HC2® HPV DNA
Description: in vitro diagnostic test

Intervention type: OTHER
Intervention: HR HC2® HPV DNA
Description: in vitro diagnostic test

Intervention type: OTHER
Intervention: Colposcopy
Description: Colposcopy

Intervention type: OTHER
Intervention: Colposcopy
Description: Colposcopy
Study: NCT05504967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oradexon
Description: With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oradexon
Description: With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Study: NCT00080847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study: NCT05504967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Study: NCT02093052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up
Description: Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education for Families
Description: Enhance children's cognitive development. In-home intervention with parents and children present.
Study: NCT01374100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Exercise
Description: The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise
Description: The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong Exercise
Description: Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qigong Exercise
Description: Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
Study: NCT00077467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03439683

Intervention type: OTHER
Intervention: Survey about patient-ventilator asynchrony
Description: Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony

Intervention type: OTHER
Intervention: Survey about patient-ventilator asynchrony
Description: Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony

Intervention type: OTHER
Intervention: Survey about patient-ventilator asynchrony
Description: Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony
Study: NCT02108678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-ME
Description: 1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Migraine Education Only
Description: 6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
Study: NCT04359381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping application
Description: kinesiotaping was applied once the menstrual pain begins (one day before menstruation) for periods of 4 to 5 days until the pain disappears and then removed it. Kinesiotaping was used for 3 successive menstruations.
Study: NCT00206544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 40 mg daily of adjunctive tamoxifen in oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 20 mg daily of adjunctive progesterone in oral capsule
Study: NCT04359381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilate exercises program
Description: Each girl in group (B) was engaged in a supervised pilate exercises program for 30 minutes per session for 3 days/week for 12 weeks except days of menstruation. Participants would be oriented to wear comfortable clothes .
Study: NCT02403466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident Handoff Bundle
Description: 1) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
Study: NCT02642497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-wound instillation of ketamine
Description: intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intra-wound instillation of normal saline
Description: intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic administration of ketamine
Description: intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
Study: NCT04669418

Intervention type: DIAGNOSTIC_TEST
Intervention: RNA expression signature
Description: Whole transcriptome profiling using RNA sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: RNA expression signature
Description: Whole transcriptome profiling using RNA sequencing
Study: NCT01376518

Intervention type: PROCEDURE
Intervention: positive end-expiratory pressure
Description: Elevation of positive end-expiratory failure for recruitment
Study: NCT01640574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
Study: NCT00395343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 100 mg tablet qd for a 24-wk treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator : placebo (unspecified)
Description: sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
Study: NCT04268823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule 300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule 300mg
Study: NCT00080847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01361347

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk
Description: milk for milk allergic children (1:25 dilution, whole milk)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: milk
Description: milk for milk allergic children (1:25 dilution, whole milk)
Study: NCT03649152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propagermanium
Description: Immediate release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propagermanium
Description: Immediate release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule
Study: NCT01684462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Serum Albumin 20
Description: Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4\~8h, commencing within 12 hours of stroke onset

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % Normal Saline
Description: Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4\~8h, commencing within 12 hours of stroke onset
Study: NCT03746691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram HCl
Description: Citalopram HCl IV 20 mg in 100 ml saline will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
Study: NCT01409343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TrasGEX™
Description: Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
Study: NCT03746691

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
Study: NCT04258579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROTECT with Technology Augmentation
Description: PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.
Study: NCT04387097

Intervention type: DRUG
Intervention: remifentanil
Description: postoperative drip-infusion of remifentanil
Study: NCT04025593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m2 day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2 day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50mg/m2 day 1
Study: NCT00383474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given orally
Study: NCT04025593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50mg/m2 day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m2, max 2mg day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m2, max 2mg day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 60mg/m2, max 100mg day 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60mg/m2, max 100mg day 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 420mg/day qd
Study: NCT01779219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iMRI-guided brain tumour biopsy
Description: The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic frameless brain tumour biopsy
Description: The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
Study: NCT00534313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Solution, intravenous, monthly, short-term = 24 weeks (6 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Solution, intravenous, monthly, short-term = 24 weeks (6 months)
Study: NCT04025593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg day1-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: 20mg day 1,4,8,11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: decitabine 10mg/m2 day-5 to day-1
Study: NCT00971126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib (Nexavar®), thalidomide (Thado®)
Description: Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study.
Study: NCT02429856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCORPIO™
Description: subjects randomized at surgery to receive 1 of the 2 specified implants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCORPIO™
Description: subjects randomized at surgery to receive 1 of the 2 specified implants
Study: NCT00206544

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: adjunctive placebo daily in oral capsule
Study: NCT05440903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace
Description: A smartphone application that provides users with mindfulness and meditation sessions.
Study: NCT00534313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Solution, intravenous, monthly, short-term = 24 weeks (6 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
Study: NCT00725842

Intervention type: BIOLOGICAL
Intervention: Peg-IFN alfa-2b
Description: Peg-IFN alfa-2b administered in accordance with approved labeling

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin administered in accordance with approved labeling
Study: NCT02243462

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced Air Warmer
Description: A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable blanket. The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket.

Intervention type: OTHER
Group type: OTHER
Intervention: No pre-op warming
Description: No forced air warming of the patient prior to being taken in for surgery
Study: NCT03841747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab IV Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
Study: NCT04097951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combinations
Description: Montelukast and Bepotastine Combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combinations
Description: Montelukast and Bepotastine Combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combinations
Description: Montelukast and Bepotastine Combination
Study: NCT03002090

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron trained
Description: 1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Untrained
Description: 1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BZKL Trained
Description: 1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BZKL Untrained
Description: 1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Trained
Description: 1. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Untrained
Description: No intervention